Capmatinib (Capmatinib) effects and efficacy

CapmatinibSold under the trade name Tabrecta, it is an anti-cancer drug used to treat metastatic non-small cell lung cancer. mutation, resulting in exon skipping of the 14 gene of the MET gene encoding the membrane receptor HGFR. Capmatinibinhibits phosphorylation of wild-type and mutant variants of c-Met upon binding of its endogenous ligand hepatocyte growth factor- in In this process, it prevents c-Met-mediated phosphorylation of downstream signaling proteins, as well as c-Met-dependent proliferation and survival of tumor cells.

The effects of capmatinib were studied in a major study involving 100 patients with "METex14 skipping" mutated advanced non-small cell lung cancer whose disease had progressed after prior immunotherapy with platinum-containing or platinum-free chemotherapy. Using body scans to assess response to treatment (reduction in cancer size), 44% of patients who received capmatinib showed partial or complete reduction in cancer size. On average, this reaction lasted at least10 months. In this study, capmatinib was not compared with any other treatment or placebo (dummy treatment) in non-small cell lung cancer.

Capmatinib is metabolized mainly by CYP3A4and aldehyde oxidase. After oral administration of radiolabeled capmatinib, approximately 78% of the radioactivity is recovered in feces, of which approximately 42% is unchanged parent drug, and 22% is recovered in urine, of which a negligible amount remains unchanged parent drug. There are generic drugs that are officially on the market in Laos, and each box costs about 3 about 3,000. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.